Antibiotic resistance is no longer a future problem for wound care — it is the present operating environment. MRSA-positive surgical site infections, indolent diabetic foot ulcers colonized with biofilm-forming organisms, and post-procedural infections that refuse to resolve on standard oral antibiotics are now routine consults in metabolic, aesthetic, and functional medicine clinics. Against that backdrop, one of the most interesting molecules in the translational pipeline isn't a novel synthetic antibiotic at all. It's a peptide your patients are already making — when they're healthy enough to make it. LL-37, the only human cathelicidin, has spent the last two decades quietly accumulating one of the more impressive evidence portfolios in host-defense biology. For clinics doing meaningful wound work — post-microneedling recovery, post-surgical aesthetic cases, chronic ulcer protocols in metabolic patients — understanding LL-37 is no longer optional.
What Is LL-37?
LL-37 is a 37-residue cationic α-helical peptide cleaved from the C-terminus of its precursor protein, hCAP-18 (human cationic antimicrobial protein, 18 kDa), encoded by the CAMP gene. It is the sole member of the cathelicidin family expressed in humans, distinguishing it from other mammals which often produce multiple cathelicidins [4]. The peptide is named for its two N-terminal leucines and its length — a naming convention that betrays how recently this molecule was structurally characterized relative to its biological importance.
hCAP-18 is constitutively stored in the secondary granules of neutrophils and is also produced by epithelial cells of the skin, respiratory tract, and gastrointestinal tract, as well as by monocytes, NK cells, B cells, and mast cells [2][4]. Extracellular cleavage by proteinase 3 (in neutrophils) or kallikreins (in keratinocytes) liberates the active LL-37 fragment. Once free, the peptide adopts an amphipathic α-helical conformation in the presence of anionic membranes — and that conformational switch is the entire mechanistic story.
The cationic face of the helix is electrostatically attracted to the negatively charged phospholipid headgroups of bacterial membranes (phosphatidylglycerol, cardiolipin, LPS), while the hydrophobic face inserts into the lipid bilayer. At sufficient local concentration, LL-37 oligomerizes and forms transmembrane pores — the so-called 'carpet' or toroidal pore models — producing rapid membrane depolarization and cell death [3]. Mammalian membranes, dominated by zwitterionic phosphatidylcholine and cholesterol, are largely spared at physiologic concentrations. That selectivity is the foundation of LL-37's therapeutic window.
But pore formation is only half the molecule. LL-37 is also a potent host-cell modulator: it binds LPS and neutralizes endotoxin, chemoattracts neutrophils, monocytes, and T cells via FPR2/FPRL1, promotes keratinocyte migration, stimulates angiogenesis through endothelial FPRL1 signaling, and modulates TLR responses to dampen excessive inflammation while preserving pathogen clearance [2][3]. In wound biology, that combination — direct bactericidal activity plus pro-resolution immune signaling plus angiogenic and re-epithelialization cues — is essentially the wishlist.
The Research
Broad-Spectrum Antimicrobial Activity
LL-37 demonstrates activity against Gram-positive organisms (including MRSA and VRE), Gram-negative organisms (E. coli, P. aeruginosa, K. pneumoniae), mycobacteria, certain enveloped viruses, and Candida species [1][4]. Minimum inhibitory concentrations in vitro typically fall in the 1–50 µg/mL range depending on organism and assay conditions, with notable activity preserved in the presence of physiologic salt concentrations that inactivate many other defensins. Critically, because the mechanism is membrane disruption rather than enzymatic inhibition of a single bacterial target, the resistance development curve is steep and slow — bacteria cannot easily mutate their way out of having an anionic membrane.
Fry's 2018 review in Surgical Infections is worth reading in full for any clinic doing post-procedural wound management; it frames antimicrobial peptides, and LL-37 in particular, as one of the most plausible near-term answers to the antibiotic resistance crisis in surgical practice [1].
The MRSA Wound Model
The 2021 Simonetti et al. study in Antibiotics is arguably the most clinically suggestive piece of preclinical data to date [5]. Investigators established full-thickness wounds in mice, inoculated them with a clinical MRSA isolate, and compared topical LL-37 against vancomycin, linezolid, and saline controls. LL-37-treated wounds showed statistically significant reductions in bacterial bioburden (CFU/g tissue), accelerated re-epithelialization on histology, and — importantly — reduced inflammatory infiltrate scoring at the wound margin. The peptide outperformed or matched the comparator antibiotics on bioburden while uniquely also improving the histologic quality of healing tissue.
That dual signal — antimicrobial plus pro-healing — is what separates LL-37 from a conventional topical antibiotic in the research literature. A standard antibiotic clears the organism but does nothing for the wound bed; LL-37, in preclinical models, appears to do both [5].
Pulmonary and Mucosal Findings
Tjabringa and colleagues have extensively characterized LL-37's role in airway biology, where the peptide is produced by bronchial epithelium and contributes to first-line defense against respiratory pathogens [2]. Low LL-37 expression has been associated with increased infection susceptibility in conditions like cystic fibrosis and morbus Kostmann (severe congenital neutropenia). While respiratory applications are outside the typical aesthetic or metabolic clinic scope, the body of mucosal research is mechanistically informative — it establishes that LL-37 functions as a true host-defense peptide across epithelial surfaces, not just in skin.
Structural Biology and the Resistance Question
Xhindoli et al. provided some of the clearest structural data on how LL-37 oligomerizes in solution and at membrane interfaces, showing that the peptide self-associates into tetramers that protect it from proteolytic degradation while preserving membrane-disrupting activity [3]. This self-assembly property is part of why LL-37 retains function in the protease-rich environment of a chronic wound bed — an environment that rapidly degrades many other peptide therapeutics.
Clinical Considerations
For practitioners considering LL-37 within physician-supervised research protocols, several practical points emerge from the literature.
First, delivery matters. LL-37 is a peptide — it is not orally bioavailable in any meaningful sense, and systemic IV administration raises legitimate concerns about off-target effects, including potential pro-inflammatory signaling at high circulating concentrations. The preclinical wound data are overwhelmingly topical or local-delivery, and that is where the translational evidence is strongest [5]. Compounded topical formulations, wound-bed irrigation protocols, and incorporation into hydrogel or collagen-matrix dressings represent the most defensible research applications.
Second, concentration is non-trivial. LL-37 exhibits a biphasic dose-response in some assays — antimicrobial and pro-healing at moderate concentrations, but potentially cytotoxic to host cells at very high concentrations, particularly to erythrocytes and certain epithelial lines [3]. Research protocols should reference established preclinical dosing ranges rather than improvising upward.
Third, patient selection is where clinical judgment earns its keep. The populations most likely to benefit, based on the underlying biology, are those with documented or suspected endogenous LL-37 insufficiency: poorly controlled diabetics with chronic wounds, patients on chronic corticosteroids, vitamin D-deficient patients (vitamin D directly upregulates CAMP gene expression), and patients with recurrent skin infections that have failed conventional topicals. Conversely, patients with rosacea or certain inflammatory dermatoses where LL-37 dysregulation is already implicated warrant more caution — the peptide is not a universal good.
LL-37 is not a replacement for surgical debridement, glycemic control, or offloading. It is an adjunct studied in the context of wounds where the underlying biology of host defense is already compromised.
Fourth, document everything. Because LL-37 protocols sit in a research context, the standard expectations apply: informed consent specifically addressing the investigational nature of the peptide, baseline and serial wound photography with measurement, microbiologic sampling where clinically indicated, and clear outcome metrics defined before initiation.
What to Look for in a Source
LL-37 is a 37-residue peptide synthesized by solid-phase Fmoc chemistry. That length puts it at the upper end of routine synthesis difficulty — meaning crude purity off the resin is often mediocre, and the difference between a credible research-grade preparation and a poor one is enormous. Truncation products (LL-36, LL-35, etc.) and deletion sequences can retain partial activity but also alter the pharmacology unpredictably. For a peptide whose mechanism depends on precise amphipathic helix formation, sequence fidelity is not negotiable.
Practitioners sourcing LL-37 for research use should require, at minimum: HPLC purity ≥98% with the chromatogram attached to the COA, mass spectrometry confirmation of the expected molecular weight (4493.3 Da for the free acid form), residual TFA content quantified, endotoxin testing (LAL assay) given that LL-37's biology specifically intersects with LPS, and documentation of cGMP-compliant manufacturing with full chain-of-custody. A vendor that cannot produce these documents on request is not a vendor a clinic should be using for any peptide, let alone one this structurally demanding.
Lot-to-lot consistency is the other tell. Reputable suppliers will provide historical COA data across lots; activity-based variation in a peptide like LL-37 is a direct reflection of synthesis and purification rigor.
Why This Matters for Your Practice
The clinical wound-care market is increasingly bifurcated. On one end, hospital wound centers manage advanced cases with HBO, bioengineered skin substitutes, and aggressive surgical management. On the other end, primary care and urgent care manage acute, uncomplicated wounds with conventional topicals and oral antibiotics. The middle — the chronic, indolent, sub-acute wound in a metabolically compromised or post-aesthetic-procedure patient — is exactly the space where med spas, metabolic clinics, and functional medicine practices are already operating, often without a clear adjunct beyond honey, silver, and conventional antibiotics.
LL-37, within a physician-supervised research protocol, represents a defensible, mechanism-driven addition to that toolkit. It is endogenous, structurally well-characterized, supported by preclinical data including an MRSA wound model with meaningful effect sizes [5], and it addresses the specific failure modes — bacterial bioburden, impaired re-epithelialization, dysregulated inflammation — that define the wounds your practice is most likely to see.
The business angle is also straightforward. Clinics that build serious post-procedural recovery protocols — protocols that visibly reduce infection rates, accelerate healing photography, and lower the rate of revision or remediation cases — develop referral networks and patient retention that price-competing on injectables alone never achieves. LL-37 is unlikely to be the cornerstone of that strategy on its own, but as a research-grade component of a thoughtful wound-care offering, it sits at the intersection of where the science is genuinely moving and where the clinical gap is most obvious.
The honest summary: LL-37 is not a miracle, and the human RCT data are still thin. But the mechanistic depth, the preclinical signal, and the structural plausibility are all stronger than for most peptides currently in clinical research conversations. For practitioners willing to engage the literature seriously and source responsibly, it is a molecule worth knowing — before your patients start asking about it, which, given the trajectory of antimicrobial resistance, they will.